ZONISAMIDE: EFFECTIVENESS AND SAFETY IN CHILDREN WITH EPILEPSY: A POSTMARKETING STUDY IN INTELLECTUALLY NORMAL AND DISABLED CHILDREN
DOI:
https://doi.org/10.48047/ta68dw98Keywords:
Zonisamide, Pediatric epilepsy, Seizure control, Intellectually disabled children and Adverse effectsAbstract
An analysis was done to determine zonisamide's long-term efficacy and safety in the treatment of childhood epilepsy, comparing its outcomes for intellectually normal and intellectually disabled children. Among the 349 subjects, all were younger than 15 years of age; they were divided into two groups based on their intellectual abilities: the intellectually normal group (n=184) and the intellectually disabled group (n=165). It was found that 62 percent of subjects improved on seizure control over the previous month, with 78 percent of subjects responding better than 45 percent of subjects with intellectual disabilities. There is some evidence that zonisamide is not only effective in partial and generalized seizures, but it is also superior in this case when applied to people who are intellectually normal. There were 24 percent of patients who reported having adverse effects that were more severe when monotherapy was used compared to combination therapy. It is clear that zonisamide may be useful in treating partial and generalized seizures in children, but adverse events should be monitored, especially when used in combination with other medications.
Downloads
References
Seino M, Ohkuma T, Miyasaka M, et al. Evaluation of the drug efficacy of AD-810 (zonisamide). Results of double-blind study in comparison with carbamazepine (in Japanese). J Clin Exp Med 1988;144:275—91.
Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993;15:67—73.
Wilder BJ, Ramsay RE, Browney T, Sackellares JC. A multicenter double-blind, placebo controlled study on zonisamide on medically refractory patients with complex seizures. Epilepsia 1985;26:545.
Oguni H, Hayashi K, Fukuyama Y, Iinuma K. Phase III study of a new antiepilepsy AD-810, zonisamide in childhood epilepsy (in Japanese). Jpn J Pediatr 1988;41:439—50.
Yamatogi Y, Ohtahara S. Current topics of treatment. In: Ohtahara S, Roger J, editors. New trends in pediatric epileptology. 1991. p. 136—48.
Iinuma K, Handa I, Fueki N, Yamamoto K, Kojima A, Haginoya K. Effects of zonisamide (AD-810) on refractory epilepsy in children: special reference to temporal lobe abnormalities. Curr Ther Res 1988;43:281—90.
Guberman A. Monotherapy or polytherapy for epilepsy? Can J Neurol Sci 1998;25:S3—8.
Fujita Y, Okubo O, Noguchi Y, Nishimura A, Fuchigami T, Harada K. Zonisamide-induced hidropoietic disorder in patients with childhood epilepsy. J Nihon Univ Med Assoc 1995;54:658—62.
Okumura A, Hayakawa F, Kuno K, Watanabe K. Oligohidrosis caused by zonisamide. No To Hattatsu 1996;28:44—7 (in Japanese).
Shimizu T, Yamashita Y, Satoi M, et al. Heat stroke-like episode in a child caused by zonisamide. Brain Dev 1997;19:366—8.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
